Camizestrant

• PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CAMIZESTRANT PLUS RIBOCICLIB IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE (HR+) BREAST C… Recruiting
  2024-520027-88-00 Phase II 2 countries Medica Scientia Innovation Research S.L.
• A trial to learn how well saruparib with camizestrant works and how safe it is in adults with advanced breast cancer that is hormone recepto… Recruiting
  2023-504180-16-00 Phase III 10 countries AstraZeneca AB
• A first-in-human dose escalation and expansion study to evaluate the safety, and tolerability of AZD8421 alone or in combination in particip… Recruiting
  2023-507305-33-00 Phase I (FiH) 1 country Astrazeneca AB
• An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting
  2023-504031-41-00 Phase III 16 countries AstraZeneca AB
• A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended
  2022-501024-20-00 Phase III 14 countries Astrazeneca AB
• A randomized, double-blind, Phase III Study of AZD9833 plus CDK4/6 inhibitor in patients with metastatic breast cancer with detectable ESR1 … Ended
  2023-503990-39-00 Phase III 12 countries AstraZeneca AB
• Study of AZD5305 as Monotherapy and with Anti-Cancer Agents in Patients with Advanced Solid Malignancies Ended
  2022-502856-29-00 Phase I (FiH) 5 countries AstraZeneca AB
• A Randomised, Double-Blind, Phase III Study of AZD9833 plus Palbociclib versus Anastrozole plus Palbociclib in Patients with ER-Positive HER… Ended
  2023-503995-26-00 Phase III 13 countries AstraZeneca AB
• A trial to learn how camizestrant (AZD9833) works compared to fulvestrant and how safe it is in women with advanced breast cancer who have g… Ended
  2023-504974-40-00 Phase II 7 countries AstraZeneca AB

Showing 1–9 of 9 trials